Plus Therapeutics Launches CNSide® Diagnostic in Texas
Plus Therapeutics, Inc. (Nasdaq: PSTV), a forward-thinking clinical-stage pharmaceutical company, is gearing up to launch its CNSide cerebrospinal fluid (CSF) assay platform and testing services in Texas. This notable rollout is aimed for August 2025 and marks a significant advance in diagnostics for central nervous system (CNS) cancers. The company focuses on facilitating better patient care specifically in National Cancer Institute (NCI) Designated Cancer Centers and major healthcare systems.
Targeting NCI Designated Cancer Centers
The initial commercial focus of CNSide involves collaboration with leading institutions such as the University of Texas - Southwestern, MD Anderson Cancer Center, and Texas Oncology. These centers have previously utilized the CNSide assay to address the challenges of leptomeningeal metastases (LM) in patients, a serious condition that often complicates cancer treatment.
The Importance of CNSide Assay
Dr. Michael Youssef, a noted Assistant Professor in Neurology at UT Southwestern Medical Center, emphasized the CNSide assay's critical role in guiding treatment decisions and monitoring patient disease progression. With its advanced detection capabilities, this assay is set to become an essential tool in the management of patients affected by CNS-related cancers.
Accessible Testing Services and Future Expansion
Patients who are at risk for LM should engage with their healthcare providers concerning the CNSide assay. Alongside making assays available, Plus Therapeutics plans to broaden the accessibility of these testing services over the next year, supplying clinicians with precise tools to aid in effective treatment strategies.
Comprehensive Diagnostic Capabilities
The CNSide CSF Assay is a proprietary platform capable of identifying tumor cells that have spread to the CNS, addressing a pressing need as CNS metastases impact a significant percentage of adult cancer patients. Shockingly, without adequate diagnosis, many of these patients find themselves receiving only palliative care.
High Sensitivity and Specificity in Diagnosis
The CNSide assay boasts impressive metrics with over 11,000 tests performed since 2020 across 200 cancer institutions. The assay demonstrates a sensitivity of 92% and specificity of 95%, influencing treatment decisions in over 90% of cases. This established performance starkly contrasts with traditional CSF cytology, which is dated and often creates challenges in timely diagnosis.
Understanding Leptomeningeal Metastases
Leptomeningeal metastases can severely impact patients with advanced cancer and are commonly associated with types such as breast cancer and melanoma. With a median survival rate of only a few months, there is a dire need for new approaches in treating and managing this condition.
About CNSide Diagnostics
CNSide Diagnostics, LLC operates as a subsidiary of Plus Therapeutics, dedicated to developing innovative diagnostic tests tailored to detect CNS metastases. Their technology allows for detailed molecular analysis that considerably enhances patient management for those at risk of LM.
About Plus Therapeutics, Inc.
Plus Therapeutics is headquarterd in Houston and is devoted to developing targeted therapies for difficult-to-treat CNS tumors. By leveraging advanced methods of drug delivery combined with localized beta radiation, Plus Therapeutics aims to transform treatment outcomes for patients suffering from conditions like recurrent glioblastoma and LM.
Frequently Asked Questions
What is the CNSide® Diagnostic?
The CNSide® Diagnostic is a proprietary cerebrospinal fluid assay developed to detect tumor cells that have metastasized to the central nervous system, particularly important for patients with various carcinomas and melanomas.
When is the CNSide Diagnostic launching in Texas?
Plus Therapeutics plans to launch the CNSide Diagnostic in Texas in August 2025 to enhance cancer patient care and monitoring.
Which institutions will use the CNSide Diagnostic?
Initial focus will be on leading cancer centers including the University of Texas - Southwestern and MD Anderson Cancer Center, where it will be used to improve patient outcomes.
How effective is the CNSide Diagnostic?
The CNSide assay has demonstrated a sensitivity of 92% and specificity of 95%, effectively influencing treatment decisions in over 90% of cases since its use began.
How can patients access the CNSide Diagnostic?
Patients can consult with their healthcare providers to learn more about the CNSide Diagnostic and discuss potential testing options available at designated cancer centers.
